Life Sciences Real Estate

Life sciences real estate emerged as a recognized institutional commercial property sector in the United States during the 1990s and 2000s and exploded into one of the most heavily sought-after asset classes during the 2020-2022 period, driven by record levels of venture capital and private equity investment in biopharmaceutical and genomics companies following the COVID-19 pandemic. The sector's defining characteristic is the highly specialized nature of the facilities required: laboratory space demands infrastructure — specialized HVAC systems, high electrical capacity, vivarium capabilities, fume hoods, and chemical storage — that traditional office buildings cannot provide and that is expensive to install or retrofit.

The U.S. life sciences real estate market is intensely concentrated in a small number of established innovation clusters. Greater Boston (particularly Cambridge and the Route 128 corridor), the San Francisco Bay Area (South San Francisco and the broader Bay Area), San Diego (Torrey Pines and UTC submarkets), and the Research Triangle Park area in North Carolina collectively account for the large majority of institutional-quality life sciences real estate in the country. These clusters exist because of their proximity to world-class research universities (MIT, Harvard, UCSF, UCSD), major academic medical centers, venture capital ecosystems, and the deep talent pools of scientists and engineers those institutions generate. Secondary clusters in markets such as Seattle, New York/New Jersey, Philadelphia, and Houston have grown in scale and importance but have historically commanded lower rents and attracted different tenant profiles.

Life sciences tenants range from early-stage venture-backed startups that require speculative lab space with flexible lease terms to large-cap pharmaceutical companies and contract research organizations that occupy purpose-built, campus-scale facilities under long-term leases. Startups require incubator and accelerator space — small, flexible lab suites with shared equipment and services — while mature companies seek large-format wet lab and manufacturing space. Multi-tenant laboratory buildings and dedicated single-tenant campuses coexist within the sector, each with distinct financial profiles.

Rents for life sciences space are substantially higher than for conventional office space in the same market, reflecting both the elevated construction and infrastructure costs of lab buildings and the inelastic demand from well-funded tenants who place more value on location within the cluster than on rental savings. Annual rents for top-tier laboratory space in Cambridge, Massachusetts have historically exceeded $100 per square foot, compared to $50 to $70 for premier Class A office space in the same market. These premium rents generate strong NOI for landlords, but the sector also requires higher capital expenditure reserves and more specialized asset management expertise than conventional office.

The life sciences sector experienced a significant correction beginning in 2022-2023 as venture capital funding for biotech companies contracted sharply following the end of the zero-interest-rate era and the wind-down of pandemic-era biotech enthusiasm. Vacancy rates in several major life sciences clusters rose as speculative development pipeline completed, and some early-stage tenants vacated space or failed to occupy leases signed during the boom. This normalization highlighted the importance of tenant credit quality and the distinction between leasing to well-capitalized late-stage companies versus early-stage startups heavily dependent on continued VC fundraising.